Cerebral cortex (New York, N.Y. : 1991) · 2018
Amyloid Network Topology Characterizes the Progression of Alzheimer's Disease During the Predementia Stages.
СтатьяПоддержка NIH: внешняя программаПоддержка правительства СШАПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Pereira Joana B, Strandberg Tor Olof, Palmqvist Sebastian, Volpe Giovanni, van Westen Danielle, Westman Eric, Hansson Oskar, Alzheimer’s Disease Neuroimaging Initiative
Аннотация
There is increasing evidence showing that the accumulation of the amyloid-β (Aβ) peptide into extracellular plaques is a central event in Alzheimer's disease (AD). These abnormalities can be detected as lowered levels of Aβ42 in the cerebrospinal fluid (CSF) and are followed by increased amyloid burden on positron emission tomography (PET) several years before the onset of dementia. The aim of this study was to assess amyloid network topology in nondemented individuals with early stage Aβ accumulation, defined as abnormal CSF Aβ42 levels and normal Florbetapir PET (CSF+/PET-), and more advanced Aβ accumulation, defined as both abnormal CSF Aβ42 and Florbetapir PET (CSF+/PET+). The amyloid networks were built using correlations in the mean 18F-florbetapir PET values between 72 brain regions and analyzed using graph theory analyses. Our findings showed an association between early amyloid stages and increased covariance as well as shorter paths between several brain areas that overlapped with the default-mode network (DMN). Moreover, we found that individuals with more advanced amyloid accumulation showed more widespread changes in brain regions both within and outside the DMN. These findings suggest that amyloid network topology could potentially be used to assess disease progression in the predementia stages of AD.
Предметные рубрики MeSH
AgedAged, 80 and overAlzheimer DiseaseAmyloid beta-PeptidesAniline CompoundsBiomarkersBrainBrain MappingCognitive DysfunctionDiagnostic Self EvaluationDisease ProgressionEthylene GlycolsFemaleHumansMaleMemory DisordersMiddle AgedNeural PathwaysPositron-Emission TomographyProdromal SymptomsRadiopharmaceuticalsSeverity of Illness Index